Intensity Therapeutics, Inc. (INTS:NASDAQ) closed at $3.08 on November 13, 2026, down 0.65% on the day. The stock trades 79.5% below its 52-week high of $15.00 and 10.0% above its 52-week low of $2.80. Over the past year, it lost 70.2%. Intensity Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, INTS closed higher on 97 days (38%). Its best day was February 24, 2026 (+16.44%) and its worst was February 13, 2026 (-32.61%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 1 time.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors.
Find more stocks like INTS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.